Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,207 public trials 1,003 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505

Conditions
Adnexal Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +22 more
Locations
  • The University of Alabama Birmingham, Alabama, United States
  • Mount Sinai New York, United States
  • Christ Hospital Cincinnati, Ohio, United States
  • Ohio State University Columbus, Ohio, United States
View all 15 locations
View Trial Details
Recruiting

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

NCT05910827

Conditions
Advanced Cutaneous Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, +21 more
Locations
  • GenesisCare North Shore Sydney, New South Wales, Australia
  • Westmead Hospital Westmead, New South Wales, Australia
  • ICON Cancer Centre South Brisbane Brisbane, Queensland, Australia
  • Greenslopes Private Hospital Greenslopes, Queensland, Australia
View all 20 locations
View Trial Details
Recruiting

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

NCT07079475

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Beijing Chest Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China
  • Harbin Cancer Hospital Harbin, Heilongjiang, China
  • Hunan Cancer Hospital Changsha, Hunan, China
View all 17 locations
View Trial Details
Recruiting

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

NCT07375316

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University Guangzhou, Guangdong, China
  • Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences Meizhou, Guangdong, China
  • The First Affiliated Hospital of Shantou University Medical College Shantou, Guangdong, China
  • Peking University Shenzhen Hospital Shenzhen, Guangdong, China
View Trial Details
Recruiting

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

NCT07278479

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +23 more
Locations
  • Emory University Hospital Atlanta, Georgia, United States
  • United Theranostics Glen Burnie, Maryland, United States
  • Nebraska Cancer Specialists Omaha, Nebraska, United States
  • United Theranostics Princeton, New Jersey, United States
View Trial Details
Recruiting

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations
  • City of Hope Duarte, California, United States
  • City of Hope Huntington Beach, California, United States
  • City of Hope Irvine, California, United States
  • Levine Cancer Institute - Charlotte Charlotte, North Carolina, United States
View all 24 locations
View Trial Details

Related conditions